Literature DB >> 27163230

Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.

Qun Lv1, Na Rong1, Li-Jia Liu1, Xiao-Lin Xu1, Jian-Ting Liu1, Feng-Xie Jin2, Chun-Mei Wang1.   

Abstract

Hepatocellular carcinoma is one of the leading causes of malignancy-related death in China. Its therapy in clinics is a big challenge. Ginsenoside Rh2 is one of the most notable cancer-preventing components from red ginseng and it has been reported that ginsenoside Rh2 exhibited potent cytotoxicity against human hepatoma cells. Rh2 exists as two different stereoisomeric forms, (20S)-ginsenoside Rh2 and (20R)-ginsenoside Rh2. Previous reports showed that the Rh2 epimers demonstrated different pharmacological activities and only (20S)-ginsenoside Rh2 showed potent proliferation inhibition on cancer cells in vitro. However, the in vivo anti-hepatoma activity of (20R)-ginsenoside Rh2 and (20S)-ginsenoside Rh2 has not been reported yet. This work assessed and compared the anti-hepatoma activities of (20S)-ginsenoside Rh2 and (20R)-ginsenoside Rh2 using H22 a hepatoma-bearing mouse model in vivo. In addition, hematoxylin and eosin staining, the deoxynucleotidyl transferase dUTP nick-end labeling assay, and the semiquantitative reverse transcriptase polymerase chain reaction method were used to further study the apoptosis of the tumors. The results showed that both (20S)-ginsenoside Rh2 and (20R)-ginsenoside Rh2 suppressed the growth of H22 transplanted tumors in vivo, and the highest inhibition rate could be up to 42.2 and 46.8 %, respectively (p < 0.05). Further, hematoxylin/eosin staining and the deoxynucleotidyl transferase dUTP nick-end labeling assay indicated that both (20R)-ginsenoside Rh2 and (20S)-ginsenoside Rh2 could induce H22 hepatoma tumor cell apoptosis, with apoptosis indexes of 3.87 %, and 3.80 %, respectively (p < 0.05). Moreover, this effect was accompanied by downregulating the level of Bcl-2 mRNA. In conclusion, both (20S)-ginsenoside Rh2 and (20R)-ginsenoside Rh2 can suppress the growth of H22 hepatomas without causing severe side effects, and this effect is associated with the induction of apoptosis. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27163230     DOI: 10.1055/s-0042-101764

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  9 in total

1.  MicroRNA-146a-5p enhances ginsenoside Rh2-induced anti-proliferation and the apoptosis of the human liver cancer cell line HepG2.

Authors:  Weiwen Chen; Shuai Chu; Haixia Li; Yurong Qiu
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

2.  Korean Red Ginseng water extract arrests growth of xenografted lymphoma cells.

Authors:  Jae Gwang Park; Young-Jin Son; Adithan Aravinthan; Jong-Hoon Kim; Jae Youl Cho
Journal:  J Ginseng Res       Date:  2016-08-04       Impact factor: 6.060

3.  Ginsenoside Rh2 inhibits human A172 glioma cell proliferation and induces cell cycle arrest status via modulating Akt signaling pathway.

Authors:  Kai-Fei Li; Chun-Min Kang; Xiao-Feng Yin; Hai-Xia Li; Zhuo-Yu Chen; Yao Li; Qiong Zhang; Yu-Rong Qiu
Journal:  Mol Med Rep       Date:  2017-12-05       Impact factor: 2.952

4.  Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.

Authors:  Honglin Li; Nan Huang; Weikang Zhu; Jianchun Wu; Xiaohui Yang; Wenjing Teng; Jianhui Tian; Zhihong Fang; Yingbin Luo; Min Chen; Yan Li
Journal:  BMC Cancer       Date:  2018-05-22       Impact factor: 4.430

Review 5.  Saponins from Chinese Medicines as Anticancer Agents.

Authors:  Xiao-Huang Xu; Ting Li; Chi Man Vivienne Fong; Xiuping Chen; Xiao-Jia Chen; Yi-Tao Wang; Ming-Qing Huang; Jin-Jian Lu
Journal:  Molecules       Date:  2016-10-05       Impact factor: 4.411

6.  Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer.

Authors:  Chao Hong; Dan Wang; Jianming Liang; Yizhen Guo; Ying Zhu; Jiaxuan Xia; Jing Qin; Huaxing Zhan; Jianxin Wang
Journal:  Theranostics       Date:  2019-06-09       Impact factor: 11.556

Review 7.  Advances in the chemistry, pharmacological diversity, and metabolism of 20(R)-ginseng saponins.

Authors:  Chaoming Wang; Juan Liu; Jianqiang Deng; Jiazhen Wang; Weizhao Weng; Hongxia Chu; Qingguo Meng
Journal:  J Ginseng Res       Date:  2019-01-31       Impact factor: 6.060

Review 8.  Anticancer Activities of Ginsenosides, the Main Active Components of Ginseng.

Authors:  Heeok Hong; Delgerzul Baatar; Seong Gu Hwang
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-03       Impact factor: 2.629

9.  Enhanced production of ginsenoside Rh2(S) from PPD-type major ginsenosides using BglSk cloned from Saccharibacillus kuerlensis together with two glycosidase in series.

Authors:  Muhammad Zubair Siddiqi; Hipolito Amaral Ximenes; Bong-Kyu Song; Hye Yoon Park; Woong Hee Lee; Hyosang Han; Wan-Taek Im
Journal:  Saudi J Biol Sci       Date:  2021-05-01       Impact factor: 4.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.